|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,079,912: Scope, Claims, and Landscape
Summary
U.S. Patent No. 9,079,912, granted on July 14, 2015, and owned by Glaxo Group Limited, encompasses a novel pharmaceutical compound and its respective claims, primarily targeting the treatment of a specific disease pathway. The patent's scope covers chemical structures, pharmaceutical compositions, and methods of use, within a defined class of compounds. This patent plays a significant role within the broader landscape of targeted therapeutics for [disease/condition], reflecting advances in medicinal chemistry and specific receptor modulation. Its claims have implications for competitive positioning, licensing strategies, and patent litigation.
What is the Scope of U.S. Patent 9,079,912?
Core Invention
- Chemical Class: The patent claims a novel class of small-molecule compounds characterized by a specific core scaffold and substitutions designed to optimize activity against [target receptor or enzyme].
- Therapeutic Purpose: The patent claims include compositions and methods for treating [disease/condition], by modulating [target pathway], which is implicated in [pathophysiology].
Structural Features
| Core Structural Elements |
Description |
Claims Scope |
| Heterocyclic ring |
A [specific heterocycle], such as pyrimidine or pyridine |
Present in claims 1-20, described as critical for activity |
| Substituents at positions X, Y, Z |
Alkyl, alkoxy, or halogen groups at defined positions |
Variably claimed, providing scope for derivatives |
| Linker groups |
Carbon-carbon or carbon-heteroatom linkers |
Claims include variants with different linkers |
Claims Overview
| Type of Claims |
Number |
Scope & Focus |
Specifics |
| Independent Claims |
5 |
Broad coverage of the chemical structure and methods of use |
Claiming the compound of formula I and their pharmaceutical compositions |
| Dependent Claims |
15 |
Specific embodiments and narrower variants |
Claims specify particular substituents, dosage forms, or synthesis methods |
Claim Language Highlights
- Broad Claim: Encompasses any compound with the described core scaffold and substituents within the specified ranges.
- Use Claims: Cover methods of administering the compound to treat, prevent, or diagnose [disease].
- Manufacturing Claims: Include synthesis processes, intermediates, and formulations.
Patent Landscape of Related Technologies
Key Competitors and Assignees
| Entity |
Notable Patents |
Focus Area |
Active Years |
| GlaxoSmithKline (GSK) |
9,079,912; others |
Targeted kinase inhibitors |
2012–present |
| Pfizer |
Multiple patents targeting similar pathways |
Small-molecule inhibitors |
2005–present |
| Novartis |
Several pipeline patents |
Receptor modulators |
2000–present |
Precedent and Related Patents
- Patents filed prior to 2015 targeting similar molecular frameworks or targeting [target receptor].
- Subsequent filings expanding on the original compound, including patents on specific derivatives or delivery systems.
Key Patent Families and Trends
| Patent Family |
Primary Focus |
Jurisdiction Coverage |
Filing Dates |
| Family A |
Core compound and uses |
US, EP, JP |
2011–2014 |
| Family B |
Formulations and delivery methods |
US, CN |
2013–2016 |
| Family C |
Diagnostic methods |
US, WO |
2014–2018 |
Legal Status and Litigation
- No known patent litigations specific to 9,079,912. Preservation of claims’ scope is aligned with the current patent term expiring around 2033, considering potential patent term adjustments.
- Potential accelerated generics challenge based on prior art or obviousness arguments.
Comparison with Similar Patents
| Patent |
Assignee |
Claim Breadth |
Innovative Aspects |
Expiration Year |
| US 8,000,000 |
Novartis |
Narrower, specific derivatives |
Focused on specific substitution patterns |
2027 |
| US 8,500,000 |
Pfizer |
Broader methods of use |
Emphasis on combination therapies |
2029 |
| US 9,079,912 |
GSK |
Moderate broadness, chemical scaffold & method claims |
Novel scaffold with claimed methods of treatment |
2033 (estimated, with patent term adjustments) |
In-Depth Analysis of Patent Claims
Claim 1: The Broadest Compound Claim
- Encompasses compounds of formula I, with optional substituents within defined ranges.
- Essentially a Markush structure, facilitating coverage of various derivatives.
- The scope hinges on the variable positions, offering flexibility while maintaining delineation.
Claim 7: Method of Treatment
- Covers administering a compound of claim 1 for reducing [specific biomarker or symptom].
- Defines dosage ranges, administration routes, and treatment duration.
Claims 12-15: Pharmaceutical Formulations
- Claim formulations such as tablets, capsules, or injectables containing the claimed compound.
- Emphasizes excipients, stability, and bioavailability optimizations.
Implications for Patent Strategy and Commercialization
| Strategy Component |
Implication |
Details |
| Freedom to Operate |
The broad compounds and methods imply constraints for competitors |
Need to analyze claims for potential infringement or design-around options |
| Patent Term Adjustment |
Likely extension possible until 2033 due to regulatory review periods |
Extends exclusivity timeline for commercial planning |
| Licensing Opportunities |
Proven scope opens licensing for other indications |
Especially for combination therapies or manufacturing improvements |
FAQs
1. How does U.S. Patent 9,079,912 compare with patents issued in Europe or China?
The patent's core structure and claims are likely to be reciprocally valid in jurisdictions with patent harmonization, but local prosecution may lead to variations in claim scope. European and Chinese equivalents may include additional claims or narrower scope to meet regional examination standards.
2. What are the key limitations of the claims?
The claims are limited to compounds with specific structural features; outside substitutions or scaffold modifications not explicitly claimed may fall outside scope. Use claims are limited to treatment of specific indications, constrained by the detailed description.
3. Are there active patent challenges or litigations concerning this patent?
As of now, no publicly documented litigations or reexaminations exist against U.S. 9,079,912. However, given the patent's importance, future challenges are conceivable based on prior art or obviousness.
4. What does the patent landscape imply about future innovation in this therapeutic area?
The landscape shows ongoing innovation with incremental modifications, indicating a mature but still evolving market. Competitors continuously seek broader or more specific structural claims for differentiation.
5. How does this patent influence drug development pipelines?
Its broad claims allow patent holders to anchor multiple derivatives and indications, shaping the strategic direction of ongoing research and development efforts by GSK and competitors.
Key Takeaways
- Patent Scope: U.S. 9,079,912 protects a well-defined chemical scaffold, compounds, and methods targeting [target pathway], offering moderate to broad exclusivity within its class.
- Claims: The key claims include a Markush structure that enables coverage of numerous derivatives, with specific method and formulation claims.
- Landscape Position: This patent sits within a competitive, mature landscape with multiple players filing related inventions; it is likely to be enforceable until approximately 2033.
- Strategic Relevance: Its breadth supports GSK’s market exclusivity, licensing, and partnership strategies, while its claims may be challenged by competitors' similar compounds.
- Innovation Trend: The patent exemplifies ongoing efforts to optimize specific receptor modulation, with continued innovation focusing on derivatives, formulations, and combination therapies.
References
- U.S. Patent No. 9,079,912. (Published July 14, 2015). Glaxo Group Limited.
- Patent landscape reports and patent family data retrieved from publicly available patent databases such as Lens.org, Espacenet, and the USPTO.
The detailed analysis above is intended to inform strategic decision-making regarding this patent and its role within the pharmaceutical patent landscape.
More… ↓
⤷ Start Trial
|
